FGFR1 antagonists(Fibroblast growth factor receptor 1 antagonists), FGFR2 antagonists(Fibroblast growth factor receptor 2 antagonists), FGFR3 antagonists(Fibroblast growth factor receptor 3 antagonists)

Therapeutic Areas

NeoplasmsDigestive System DisordersOther Diseases+ [3]

Active Indication

FGFR2 fusion or rearranged CholangiocarcinomaAchondroplasiaUrothelial Carcinoma of the Urinary Bladder+ [8]

Inactive Indication

Advanced Bile Duct CarcinomaBladder CancerEndometrial Carcinoma+ [25]

Originator Organization

QED Therapeutics, Inc.

Active Organization

QED Therapeutics, Inc.

Helsinn Birex Pharmaceuticals Ltd.LianBio Development (HK) Ltd.

+ [4]

Inactive Organization

Helsinn Healthcare SA

Novartis Pharmaceuticals Corp.

Shanghai Lianbio Development Co., Ltd.

+ [6]

License Organization

Xediton Pharmaceuticals, Inc.

Novartis AG

Kyowa Kirin Co., Ltd.

+ [5]

Drug Highest PhaseApproved

First Approval Date

United States (28 May 2021),

FGFR2 fusion or rearranged Cholangiocarcinoma

RegulationBreakthrough Therapy (United States), Accelerated Approval (United States), Orphan Drug (United States), Rare Pediatric Disease (United States), Orphan Drug (European Union), Breakthrough Therapy (China), Orphan Drug (Australia), Fast Track (United States)

Structure/Sequence

Molecular FormulaC26H34Cl2N7O7P

InChIKeyGUQNHCGYHLSITB-UHFFFAOYSA-N

CAS Registry1310746-10-1

Clinical Trials associated with Infigratinib Phosphate

NCT07393373

/ Enrolling by invitationPhase 2

Phase 2, Open-Label, Long-Term, Extension (OLE) Study of Infigratinib, an FGFR 1-3-Selective Tyrosine Kinase Inhibitor, in Children With Hypochondroplasia: ACCEL OLE

Phase 2, multicenter, OLE study to evaluate the long-term safety, tolerability, and efficacy of infigratinib, an FGFR (fibroblast growth factor receptor) 1-3-selective tyrosine kinase inhibitor, in participants with Hypochondroplasia (HCH) who previously completed ACCEL 2/3, and potentially additional participants who completed ACCEL. Participants rolling over directly from the observational ACCEL study must have had at least a 6-month period of growth assessment in that study.

Start Date21 Apr 2026

Sponsor / Collaborator

QED Therapeutics, Inc.

NCT07169279

/ RecruitingPhase 2

Phase 2b, Randomized, Double-Blind, Placebo-Controlled Clinical Trial, Preceded by a Single Ascending Dose Portion and a Phase 2 Open-Label Portion, to Evaluate the Safety and Efficacy of Oral Infigratinib in Infants and Young Children With Achondroplasia

This is a Phase 2, multicenter, randomized, placebo-controlled study to evaluate the safety and efficacy of infigratinib in participants < 3 years old with ACH. The purposes of the SAD and Phase 2 portions are to identify and confirm the dose of infigratinib to be used in the Phase 2b portion, based on safety and PK. The purpose of the Phase 2b, placebo-controlled portion is to evaluate the safety and efficacy of infigratinib in children < 3 years old with ACH at the selected dose.

Start Date19 Nov 2025

Sponsor / Collaborator

QED Therapeutics, Inc.

NCT06873035

/ Enrolling by invitationPhase 2/3

A Phase 2/3, Multicenter, Open-Label Phase Followed by a Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Infigratinib in Children With Hypochondroplasia: ACCEL 2/3

ACCEL2/3 is a Phase 2/3 study. The purpose of the Phase 2 portion of the study (ACCEL2/3) is to evaluate the efficacy and safety, of infigratinib in children with hypochondroplasia (HCH) receiving infigratinib, at one of two doses, of who have completed at least 26 weeks of participation in QED-sponsored ACCEL (QBGJ398-004).

Start Date22 Apr 2025

Sponsor / Collaborator-

100 Clinical Results associated with Infigratinib Phosphate

100 Translational Medicine associated with Infigratinib Phosphate

100 Patents (Medical) associated with Infigratinib Phosphate

369

Literatures (Medical) associated with Infigratinib Phosphate

01 May 2026·CANCER LETTERS

Targeting FGFR1-regulated SPP1 signaling repolarizes immunosuppressive macrophages and sensitizes Hepatocellular Carcinoma to anti-PD-1 therapy

Article

Author: Fu, Jing ; Meng, Zhengyuan ; Gu, Mingye ; Jiang, Youhai ; Wang, Hongyang ; Zong, Yali ; Liu, Xiru ; Chen, Lei ; Liu, Erdong ; Li, Jingfeng ; Liu, Chunliang ; Wang, Xiang ; Chen, Jianan

The response rate to immune checkpoint blockade (ICB) in hepatocellular carcinoma (HCC) remains unsatisfactory, and the mechanisms of resistance are not fully understood. Here, we investigated the role of fibroblast growth factor receptor 1 (FGFR1) in shaping the tumor microenvironment (TME) and mediating ICB resistance. An anti-PD-1-resistant HCC model was established in mice, followed by single-cell RNA sequencing to profile TME alterations. We observed that ICB resistance was associated with FGFR1 upregulation, which activated MAPK signaling and induced SPP1 expression. This cascade promotes macrophage infiltration and M2-type polarization, while simultaneously suppressing T cell recruitment and cytotoxic function, thereby fostering an immunosuppressive microenvironment. SPP1 knockdown or neutralization significantly reduced macrophage accumulation and restored intratumoral T cell infiltration. Importantly, pharmacological inhibition of FGFR1 using BGJ398 synergized with anti-PD-1 therapy, resulting in enhanced antitumor efficacy in preclinical models. Analysis of clinical datasets further revealed that high FGFR1 expression correlated with poor responses to ICB of HCC patients. Collectively, these findings identify FGFR1 as a key mediator of ICB resistance in HCC. Targeting FGFR1 represents a promising strategy to reprogram the immunosuppressive TME and enhance response to immunotherapy, with potential additional value as a predictive biomarker.

01 Feb 2026·JBMR Plus

Inhibition of FGFR signaling with infigratinib improves linear bone growth in the female Aga2/+ mouse model of osteogenesis imperfecta

Article

Author: Chun, Cora ; Rios, Alma ; Krejci, Pavel ; Bober, Benjamin ; Kot, Alexander ; Bagheri, Roya ; Krakow, Deborah ; Wachtell, Davis ; Wight, Caroline ; Zieba, Jennifer

Abstract:

Osteogenesis imperfecta, a genetically heterogeneous disorder, is characterized by brittle bones with recurrent fractures as well as short stature. A recent study investigating cellular signaling in growth plate chondrocytes identified an increased expression of FGF receptors and elevated FGF signaling. We inhibited FGF receptor activation with the small molecule infigratinib in growing Aga2/+ mice and then characterized linear growth, cartilage growth plate histology, and bone morphometrics. Infigratinib treatment resulted in increased female femur length, increased growth plate lengths in both sexes, specifically in the proliferative zone, and reduced phospho-ERK1/2 as well as SOX9 expression in lower hypertrophic chondrocytes. Infigratinib had no impact on cortical bone but reduced male trabecular bone parameters in Aga2/+ mice. Three point bending biomechanical tests showed that Aga2/+-treated males had increased bone strength for some parameters, but reduced bone strength in treated WT males, correlating with the negative impact on trabecular bone parameters. WT and Aga2-treated male mice also showed increased serum testosterone levels. Together, these data establish FGFR as a therapeutic target for short stature in osteogenesis imperfecta and identify potential negative effects of pan-FGFR inhibition, particularly in the male skeleton.

01 Jan 2026·ARCHIVES OF DISEASE IN CHILDHOOD

Sleep-disordered breathing in children with achondroplasia assessed by polysomnography: a retrospective chart review

Article

Author: Adams, Anne-Marie ; Buchwald, Christian von ; Vandeleur, Moya ; Jacobsen, Jeppe Ravn ; Savarirayan, Ravi ; Buciek, Louise Hove ; Raj, Supriya ; Griffiths, Amanda ; Kiaer, Eva Kirkegaard ; Hove, Hanne B

Objectives:

Sleep-disordered breathing is a key childhood complication in children with achondroplasia. This retrospective study aimed to document the prevalence of sleep-disordered breathing in children with achondroplasia assessed by polysomnography.

Design:

The prevalence of sleep-disordered breathing assessed by polysomnography among children aged 0–18 years with achondroplasia from 2013 to 2024 at The Royal Children’s Hospital, Australia, was retrospectively reviewed.

Results:

The cohort included 80 children with achondroplasia (54% females, 95% confirmed molecular diagnosis) with an average number of 3.6 polysomnographies collected per child (n=288). A total of 85% (68/80) had sleep-disordered breathing and 21% reported no prior symptoms. Sleep-disordered breathing subtypes included obstructive sleep apnoea in 81% (55/68), central sleep apnoea in 3% (2/68), mixed sleep apnoea in 7% (5/68) and primary snoring in 9% (6/68). Among those with obstructive and mixed sleep apnoea, 58% (35/60) had moderate or severe obstructive sleep apnoea. In 44 children, a corresponding MRI was evaluated for foramen magnum stenosis using the Achondroplasia Foramen Magnum Score. No correlation was found with sleep-disordered breathing severity (Spearman’s coefficient (ρ)=0.03). Among 27 children who received a precision therapy for achondroplasia (vosoritide, n=18, infigratinib, n=8 and recifercept, n=1), the median respiratory disturbance index/hour improved from 2.7 (25th–75th percentile, (0.9–4.8)) to 1.1 (0.3–2.6) after 1 year of treatment compared with baseline.

Conclusions:

Sleep-disordered breathing was present in 85% of 80 children with achondroplasia, with 21% being asymptomatic. Respiratory parameters did not correlate with foramen magnum stenosis severity and improved after 1 year of treatment in those treated with a precision therapy.

136

News (Medical) associated with Infigratinib Phosphate

16 Apr 2026

·allsci.com

Partner Therapeutics seeking third indication for Bizengri in NRG1 fusion-positive cholangiocarcinoma

Partner Therapeutics submitted a supplemental Biologics License Application (sBLA) to the US FDA on April 14, 2026 for Bizengri (zenocutuzumab-zbco), seeking approval for adults with advanced unresectable or metastatic cholangiocarcinoma harboring an NRG1 gene fusion. The filing marks the first regulatory submission for Bizengri in this bile duct malignancy with the aim of adding a third indication to the molecule’s existing accelerated approvals in NRG1 fusion-positive non-small cell lung cancer and pancreatic adenocarcinoma. The sBLA seeks approval without restriction to a specific line of therapy, the company said. The filing is supported by data from the eNRGy study, a basket trial evaluating zenocutuzumab-zbco across NRG1 fusion-positive solid tumors. No priority review or accelerated pathway designation was disclosed in the announcement, and the company did not provide a projected PDUFA date. Bizengri’s cholangiocarcinoma data The cholangiocarcinoma cohort of the eNRGy study generated an overall response rate of 36.8% (95% CI: 16.3, 61.6%) and a median duration of response of 12.9 months, as assessed by blinded independent central review. No patients in that cohort discontinued therapy due to adverse events, the company said. The mechanism underlying the filing differs from all currently approved CCA therapies: zenocutuzumab-zbco is a bispecific antibody that simultaneously blocks HER2/HER3 heterodimerization and NRG1 fusion interactions with HER3, disrupting downstream signaling driven by NRG1 chimeric ligands rather than the chimeric receptors targeted by FGFR inhibitors such as pemigatinib and futibatinib. NRG1 fusions are estimated to occur in fewer than 2% of cholangiocarcinoma cases, and the source material states that no approved therapies currently target this molecular subgroup in the disease. The rarity of the alteration creates a diagnostic challenge: unlike NTRK, RET, or FGFR fusions, NRG1 fusions produce chimeric ligands that are frequently missed by DNA-only next-generation sequencing panels and require tissue-based RNA testing for reliable detection. Partner Therapeutics noted this in its announcement, with Chief Development Officer Pritesh Gandhi stating that RNA testing is essential to ensure patients with NRG1-driven tumors are identified. NCCN guidelines The filing arrives alongside a notable guideline development. The National Comprehensive Cancer Network added zenocutuzumab-zbco to its oncology clinical practice guidelines for biliary tract cancers as a Category 2A subsequent-line therapy and as a Category 2B recommendation for front-line treatment of NRG1 fusion-positive cholangiocarcinoma — the latter positioning preceding any formal regulatory approval for the indication. Dr. James Cleary of Dana-Farber Cancer Institute, commenting in the release, described NRG1 gene fusions as an actionable biomarker in this disease and said the eNRGy data suggest targeted inhibition with zenocutuzumab may represent a meaningful treatment approach. The cholangiocarcinoma treatment landscape has undergone substantial change since 2020, when pemigatinib became the first targeted therapy approved in the disease. Ivosidenib followed in 2021 for IDH1-mutant CCA, futibatinib in 2022 for FGFR2 fusion-positive intrahepatic disease, and durvalumab in combination with gemcitabine and cisplatin was approved the same year for first-line biliary tract cancer regardless of biomarker status. Pembrolizumab combined with gemcitabine and cisplatin received approval in 2023 for the same unselected population. Despite this expansion, the molecular subgroup defined by NRG1 fusions has remained without a specifically labeled therapy, and the eNRGy data represent the primary clinical evidence base for this population in CCA. The sBLA adds to a field where accelerated approval pathways have played a central role, and where the durability of those approvals has varied. Infigratinib, an FGFR1–3 inhibitor that received accelerated approval in 2021 for FGFR2 fusion-positive CCA, was voluntarily withdrawn in 2024 after a confirmatory trial failed to verify clinical benefit — a precedent that underscores the regulatory risk associated with response-rate-based submissions in this disease. The eNRGy cholangiocarcinoma cohort was small, as is typical for trials enrolling rare fusion-defined populations, and the 95% confidence interval for the reported ORR is correspondingly wide. Bizengri’s existing accelerated approvals in NSCLC and pancreatic adenocarcinoma were also granted based on overall response rate and duration of response, with continued approval in those indications contingent on confirmatory trial data. The cholangiocarcinoma sBLA follows the same evidentiary model. Partner Therapeutics holds exclusive US rights to develop and commercialize zenocutuzumab-zbco under an agreement with Merus B.V., a wholly owned subsidiary of Genmab. Leave a Reply Cancel reply Your email address will not be published. Required fields are marked * Comment * Name * Email * Website

16 Mar 2026

·www.biospace.com

BioMarin Pauses Dosing, Enrollment in 2 Voxzogo Studies After Safety Signal

iStock, BeritK With Ascendis Pharma entering the achondroplasia space last month and BridgeBio on deck, BioMarin faces competition. Adding to the pressure, the company suffered a setback Monday when it halted two studies of Voxzogo in other growth-related conditions following multiple cases of hip injuries in other trials of the drug. The hits just keep on coming for BioMarin’s Voxzogo. After gaining a competitor in the achondroplasia space last month with the FDA approval of Ascendis Pharma’s Yuviwel, BioMarin is halting dosing and enrollment in trials for Turner syndrome, SHOX-deficiency and aggrecan (ACAN) deficiency. BioMarin made the decision after several slipped capital femoral epiphysis (SCFE) events were reported in two ongoing investigator-sponsored trials of the drug, according to a Monday SEC filing . SCFE occurs when the rounded head of the femur slips off the neck of the thigh bone at the growth plate, causing pain, stiffness and difficulty walking. SCFE events have not been detected in BioMarin’s Phase 2 trials of Voxzogo in the conditions studied in the investigator-sponsored trials, BioMarin said in the filing, nor in the “more than 5,000 infants and children” who have been treated with Voxzogo for achondroplasia, a genetic disorder at the root of the most common form of dwarfism. Shares of BioMarin fell about 4.6% to $55.80 in premarket trading Monday, Seeking Alpha reported , but stabilized around $58.01 when the market opened. The FDA approved Voxzogo in November 2021 as the first drug to improve growth in children with achondroplasia. The company is also developing the drug for several other growth-related conditions, including in Phase 2 trials for short stature associated with Turner syndrome and a basket study of Voxzogo in Turner syndrome, SHOX deficiency and Noonan syndrome (ACAN deficiency). Two other Phase 2 trials of Voxzogo—in hypochondroplasia and Noonan syndrome, and in people with idiopathic short stature (ISS) without ACAN-deficiency—will continue as planned, BioMarin noted in the SEC filing. ISS without ACAN-deficiency represents approximately 95% of children enrolled in the ISS trial, the biotech added. While Voxzogo was first to market in achondroplasia, the company has conceded that competition is threatening its position. During a third-quarter earnings call last year, BioMarin walked back a previous goal of hitting $4 billion in revenue by 2027, a decision that was heavily influenced by incoming competition, CEO Alexander Hardy said at the time. Approvals Ascendis Enters Achondroplasia Arena as FDA Approves First Weekly Drug Yuviwel will compete with BioMarin’s Voxzogo. Meanwhile, BridgeBio is working to bring its own achondroplasia drug, the FGFR3 blocker infigratinib, to the market. March 2, 2026 · 2 min read · Tristan Manalac Read more Voxzogo requires a daily injection, compared to Ascendis’ Yuviwel, which is given on a weekly schedule and could provide a convenience advantage for patients. Both companies are also facing potential competition from BridgeBio’s infigratinib, which in a Phase 3 trial last month “meaningfully exceeded even the most optimistic expectations” in terms of efficacy and safety, according to Truist Securities. BridgeBio expects to new drug application with the FDA in the second half of this year.

Phase 3Drug ApprovalPhase 2Clinical Result

02 Mar 2026

·www.fiercepharma.com

Ascendis gains more altitude with FDA approval for dwarfism drug Yuviwel

Ascendis Pharma of Denmark has gained its third FDA new drug approval in the last six years as the U.S. regulator has signed off on Yuviwel as a treatment for achondroplasia. Ascendis Pharma is spiraling upward by way of its TransCon platform. For the third time in six years, the Copenhagen-based biopharma has scored an FDA approval for a rare disease medicine that was developed with its “transient conjugation” drug delivery technology. The U.S. regulator has signed off on Yuviwel, a once-weekly injection to treat children with achondroplasia, a rare genetic disorder that causes dwarfism. The accelerated approval covers children age 2 and older who have open growth plates, which are areas where cartilage develops at the end of bones, allowing them to lengthen.By providing continuous exposure to C-type natriuretic peptide (CNP) receptors, Yuviwel can counter the effects of the fibroblast growth factor receptor 3 (FGFR3) gene, which causes the protein to become overactive and restrict growth. This continuous systemic exposure to CNP over the weekly dosing interval sets Yuviwel apart in the achondroplasia treatment landscape, according to Ascendis.“The approval of once-weekly Yuviwel is a major step forward in the treatment of children with achondroplasia, giving physicians for the first time the option of prescribing a once-weekly medicine backed by compelling efficacy and excellent tolerability data from three randomized, double-blind, placebo-controlled clinical trials,” Carlos Bacino, M.D., of Baylor University and Texas Children’s Hospital, said in a release.The three trials and up to three years of open-label extension data demonstrated the ability of Yuviwel to provide improvements in annualized growth velocity versus placebo.Achondroplasia is the most common form of short-limbed dwarfism, affecting between 1 in 10,000 and 1 in 30,000 live births and preventing adults from growing taller than four feet,10 inches. The condition can increase the likelihood of spinal cord compression and respiratory blockages early in life along with other muscular and neurological problems.The company said it expects to make Yuviwel available early in the second quarter of this year. In a conference call Monday morning, Ascendis said it will reveal the price in the coming days.The nod comes with a valuable pediatric disease priority review voucher, which can be used to speed the review of a future drug application."Most of the products we're developing are getting priority review, so I'm not sure that we actually need to keep it. I think we'll sell it," Scott Smith, Ascendis' chief financial officer, said in a lighter moment during the conference call.Yuviwel’s approval comes after the FDA delayed its decision on the medicine by three months back in November. Ascendis will compete with BioMarin in the indication. The California company gained approval for its CNP treatment Voxzogo in 2021. The daily injected medicine generated sales of $927 million last year, which were up 26% and accounted for 29% of the company’s revenue in 2025.BioMarin is working on a longer-acting version of Voxzogo, BMN 333, which has shown promise in a phase 1 trial and could be launched by 2030, the company has said. BMN 333 has shown area-under-the-curve (AUC) levels greater than three times those observed in other long-acting CNP studies, BioMarin said in August of last year, referring to Ascendis’ trials for Yuviwel. AUC is a pharmacokinetic measure indicating the total exposure to a drug over time.Ascendis’ current advantage with Yuviwel is its consistent, sustained release over its weekly dosing as opposed to Voxzogo’s daily administration.Last month, BridgeBio revealed the success of a phase 3 trial of its FGFR1-3 selective tyrosine kinase inhibitor infigratinib in children with achondroplasia. BridgeBio and its partner Kyowa Kirin plan to apply for approval of infigratinib in the second half of this year.Ascendis used its TransCon technology to develop Skytrofa, a long-acting growth hormone for children which was approved in the U.S. in 2021, and Yorvipath, a hormone replacement therapy for hypoparathyroidism, which scored an FDA nod in 2024. Sales for Skytrofa reached 206 million euros ($242 million) last year, which were up 5% year over year. Yorvipath generated sales of 477 million euros ($561 million) last year, with 187 million euros ($220 million) coming in the fourth quarter."We expects Yuviwel revenue to be light this year but don't think that reflects on long-term value," analysts from ISI Evercore wrote in a note to investors. "We continue to believe our $1 billion CNP franchise peak is quite conservative."Evercore sees more sales potential for Yuviwel in Europe than in the U.S., citing sales results for Voxzogo. There are also other potential indications for the treatment. The company also is exploring the potential of Yuviwel in combination with other treatments.

Drug ApprovalPhase 3Clinical ResultPhase 1Priority Review

100 Deals associated with Infigratinib Phosphate

External Link

KEGG	Wiki	ATC	Drug Bank
D11589 D11611	Infigratinib Phosphate	L01XE	DB11886

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
FGFR2 fusion or rearranged Cholangiocarcinoma	United States	Helsinn Healthcare SA	28 May 2021

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Bile Duct Neoplasms	NDA/BLA	Switzerland	Helsinn Birex Pharmaceuticals Ltd.	30 Jan 2022
Hypochondroplasia	Phase 3	United States	-	22 Apr 2025
Hypochondroplasia	Phase 3	Australia	-	22 Apr 2025
Hypochondroplasia	Phase 3	Canada	-	22 Apr 2025
Hypochondroplasia	Phase 3	France	-	22 Apr 2025
Hypochondroplasia	Phase 3	Norway	-	22 Apr 2025
Hypochondroplasia	Phase 3	Portugal	-	22 Apr 2025
Hypochondroplasia	Phase 3	Singapore	-	22 Apr 2025
Hypochondroplasia	Phase 3	Spain	-	22 Apr 2025
Hypochondroplasia	Phase 3	Sweden	-	22 Apr 2025

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ESMO_SRC2026	Not Applicable	Central Nervous System Neoplasms	9	infigratinib	mvhxmqpnff(flkmxkqiis) = Toxicities included fatigue, visual changes, hyperphosphatemia and stomatitis. Two patients required dose reductions and four required discontinuation due to toxicity (visual changes - 1, hyperphosphatemia - 1 and fatigue - 2) yabprblteh (rjzxfpteab )	Positive	09 Mar 2026
NCT04424966 (CTgov)	Early Phase 1	Glioblastoma Multiforme \| Recurrent Malignant Glioma	7	Infigratinib	qvngqnbivd(hgbvbnzumk) = mvbqcbqosu lrcnqcemql (zfyxklsrwv, kjwpdqygnc - qqfwizxebu) View more	-	24 Oct 2025
NCT04233567 (CTgov)	Phase 2	Refractory Malignant Solid Neoplasm \| Metastatic Solid Tumor \| Advanced Malignant Solid Neoplasm ... View more	17	Infigratinib	whzpnziqpt = cqwohxyjrz nekptmdqgx (qxougumpoh, lfmoolwxgf - ljpocngndj) View more	-	10 Jun 2025
NCT04265651 (PROPEL2, Pubmed \| N Engl J Med)	Phase 2	Achondroplasia	72	Infigratinib 0.25 mg/kg	ijpibzmeos(zawuzynafz) = turcuuduza suhpdrnepp (mjwdwsbizi, 1.22 - 3.79)	Positive	27 Feb 2025
NCT04228042 (CTgov)	Phase 1/2	Renal Pelvis and Ureter Urothelial Carcinoma	15	Infigratinib	zdrntaonkd = zrktlhowjn vyleflesgj (thrypewntw, szlospxrvu - ydgiszfovq) View more	-	01 Jan 2025
NCT05019794 (Pubmed) Manual	Phase 2	FGFR2 positive Stomach Cancer FGFR2 Amplification	21	Infigratinib 125 mg	jhnpdwtmgz(txxvjdznou) = jeueljhuhs gsvgggdpfk (mrexeiqbtc ) View more	Positive	01 Dec 2024
NCT04265651 (PROPEL2, Literature) Manual	Phase 2	Achondroplasia	72	Infigratinib	okyoltznxc(aeijwsrqzc) = htnmlcvwco rezziataqm (mpgxnrybta, 1.22 - 3.79) View more	Positive	18 Nov 2024
NCT04265651 (PROPEL 2, ESPE2024)	Phase 2	Achondroplasia	72	Infigratinib 0.25 mg/kg/day	rcphlaswbe(zsqzlnwipe) = zutupiyhsr tdgikzurlu (qeenlojqit ) View more	Positive	16 Nov 2024
NCT04265651 (PROPEL2, Biospace) Manual	Phase 2	Achondroplasia \| Hypochondroplasia	-	Infigratinib (Cohort 5)	fvyugnshky(kbfqrwsegu) = pkekzjekgt faaiadbipj (ncrrqmkzzm ) View more	Positive	11 Jun 2024
NCT05544552 \| NCT02278978 \| NCT04595747 \| NCT04228042 (Pubmed \| J Urol)	Phase 1	Transitional cell cancer of the renal pelvis and ureter localised FGFR3 alterations	14	Infigratinib 125 mg	dyamocdpqu(rfbfvamlkr) = oidigwzvwn jgdikytsfe (sezdejraro ) View more	Positive	01 Jun 2024

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Infigratinib Phosphate

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation